Anti-Dengue Virus (Clone: DENV-2D22)

Pricing & Details

Product No.LT562
Dengue Virus
Formats AvailableView All
Product Type
Recombinant Monoclonal Antibody
Alternate Names
Human IgG1
Prod No.
Add to cart
LT562-250 µg
250 µg
Min: 1
Step: 1
LT562-1.0 mg
1.0 mg
Min: 1
Step: 1
Bulk quantities available. Contact us for pricing.

Antibody Details

Product Details

Reactivity Species
Expression Host
Sequenced from human survivors of who had experienced a DENV infection during travel to an endemic region.
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
≥95% monomer by analytical SEC
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Standard Overnight on Blue Ice.
Other Applications Reported In Literature ?
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.


DENV-2D22 activity is DENV-2 specific and directed against the E homodimer at the DIII + glycan loop with serotype specificity on one E protein and DII around the fusion loop on the other E protein.

Antibody clone DENV-2D22 was identified as strongly neutralizing, capable of inhibiting infection of DENV-2, and able to bind intact DENV-2 but not DIII or recombinant E3,4. DENV-2D22 also did not bind to E protein by immunoblot4. DENV-2D22 is E protein specific based on an escape mutant of DIII at R323G 3 and recognizes a complex quaternary epitope displayed on the intact virus formed by DIII and DII on two different monomers within a single dimer5. When the entire DENV-2 DIII region was inserted into the backbone sequence of a DENV-4 molecular clone to create a recombinant virus, DENV-2D22 was capable of binding and neutralization6. Only five contact residues differ between DENV-2 and -4 in DIII, and these are likely critical for binding and neutralization5.

DENV-2D22 had no detectable ability to enhance DENV infection at a typical concentration range in a Ab-dependent enhancement assay4, was capable of binding and neutralizing chimeric yellow fever-dengue vaccine virus serotype 22, and blocked viral infection of viremic blood for Ae. aegypti7.
Dengue virus (DENV) is the most common insect-transmitted virus to target humans, with an estimated 390 million infections annually1. DENVs are members of the Flaviviridae family and can be divided into four closely related but antigenically distinct serotypes2. They encode a single-stranded positive sense RNA genome and display 180 copies of envelope (E) glycoprotein and premembrane/membrane (prM/M) proteins. E glycoprotein is comprised of three structural domains, DI, DII, and DIII, and exists as a homodimer in the pre-fusion state on the mature virus particle. E undergoes multiple conformation changes during maturation and fusion.

Antigen Details

Research Area
Infectious Disease

References & Citations

1. Smith SA, de Alwis AR, Kose N, et al. mBio. 4(6):e00873-13. 2013.
2. Lecouturier V, Berry C, Saulnier A, et al. Vaccine. 37(32):4601-4609. 2019.
3. de Alwis R, Smith SA, Olivarez NP, et al. Proc Natl Acad Sci U S A. 109(19):7439-44. 2012.
4. Smith SA, Zhou Y, Olivarez NP, et al. J Virol. 86(5):2665-2675. 2012.
5. Fibriansah G, Ibarra KD, Ng TS, et al. Science. 349(6243):88-91. 2015.
6. Gallichotte EN, Widman DG, Yount BL, et al. mBio. 6(5):e01461-15. 2015.
7. Tuan Vu T, Clapham H, Huynh VTT, et al. PLoS Negl Trop Dis. 13(11):e0007142. 2019.
Elisa Sandwich Protocol

Formats Available

Prod No.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy. Ok